André discusses the growing appeal of private markets, highlighting the regulatory burdens of being public and the influx of capital seeking private equity returns. He emphasizes the inefficiencies present in pre-IPO firms, particularly in sectors like biotech, where strategic investments can yield significant returns before companies go public. The conversation underscores the importance of patience and staying power in navigating these market fluctuations.
